

Tumor Cell Biology meeting 2016

Hotel 'de Werelt' Lunteren

Tuesday November 1st, 2016

09.00 Registration and coffee

10.00 **opening** *Marcel Spaargaren*

Session I: Target- and drug-discovery

Chairs: Frank van Leeuwen and René Medema

10.15 Development and use of ovarian clear cell carcinoma patient derived xenograft models to test novel targeted therapies

J.J.Caumanns, UMCG, Groningen

10.30 MDMX and PKC δ depletion sensitizes uveal melanoma cells for Sotrastaurin and Nutlin

R.C. Heijkants, LUMC, Leiden

10.45 Potential new treatment for patients with bladder cancer with a high risk of progression to invasive disease

G. van der Horst, LUMC, Leiden

11.00 A novel approach to eliminate treatment-resistant glioblastoma

D. Putavet, Erasmus MC, Rotterdam

11.15 Coffee/Tea

Session I: Target- and drug-discovery (continued)

Chairs: Rob Wolthuis and Peter de Keizer

- 11.45 Identification of novel kinases implemented in sensitivity towards asparaginase and prednisone treatment
M. Butler, RadboudUMC, Nijmegen
- 12.00 Epigenetic cross-talk in lymphomagenesis: Histone deacetylase HDAC1 regulates histone H3K79 methylation by DOT1L in mouse T-cell lymphoma
E. M. Maliapaard, NKI-AvL, Amsterdam
- 12.15 The EMT transcription factor SNAI2 is an important driver of neuroblastoma plasticity; implications for therapy
K. Vrenken, RadboudUMC, Nijmegen
- 12.30 Pressing the cell's own brake pedal: mechanisms of tumor suppression by atypical E2F repressors
B. Westendorp, Utrecht University, Utrecht
- 12.45 A screening strategy for the discovery of drugs with potential calorie restriction mimetic activities
M. A. Zaini, UMCG, Groningen,
- 13.00 Lunch (14.00 hr: meeting project leaders)**
- 14.30 **Invited lecture**
'Oncogenic Enhancer Rearrangements in Acute Myeloid Leukemia'
Ruud Delwel, Erasmus MC, Rotterdam
- 15.15 **KWF presentation**
Wies van Roosmalen

Session II: Oncogenesis

Chair: Paul Cofffer

- 15.30 FOXOs are the linchpin in AKT-targeted therapy against Multiple Myeloma
T.A. Bloedjes, AMC, Amsterdam
- 15.45 Tuning FOXO activity is essential for tumorigenesis
M. Hornsveld, UMC Utrecht, Utrecht
- 16.00 Sialic Acid-Binding Immunoglobulin-like Lectin G influences disease onset and BCR repertoire in Chronic Lymphocytic Leukemia
S. Pal Singh, Erasmus MC, Rotterdam

16.15 Coffee/Tea

Session II: Oncogenesis (*continued*)

Chairs: Jeroen Guikema and Patrick Derksen

- 16.45 Systematic unraveling the spliceosome control of breast cancer progression
E. Koedoot, Leiden University, Leiden
- 17.00 The role of Src as an apoptotic switch in TRAIL resistant non-small cell lung cancer cells
M. de Looff, UMCG, Groningen
- 17.15 Live cell imaging of endosome-plasma membrane fusion reveals regulation of exosome release by GPCR signaling
M. Bebelman, VU, Amsterdam

- 17.30 Inactivation of atypical E2F tumor suppressors by CHK1 and 14-3-3 proteins
R. Yuan, Utrecht University, Utrecht
- 17.45 C/EBP α is crucial determinant of epithelial homeostasis by preventing epithelial-to-mesenchymal transition
A.R. Lourenço, Utrecht University, Utrecht
- 18.00 Dinner**
- 20.00 **Keynote Lecture**
- ‘Personalized medicine and kinase targeting in melanoma’
Richard Marais
Cancer Research UK Manchester Institute, Manchester, UK
- 21.00 **Disco** (sponsored by BLOKÉ) and drinks

Wednesday November 2nd, 2016

Session III: Therapy-resistance

Chairs: Linda Smit and Steven de Jong

- 09.00 Discovery of an acquired therapeutic vulnerability in PARP-inhibitor resistant BRCA1-deficient cells
M. Barazas, NKI-AvL, Amsterdam
- 09.15 PARG is a novel factor of PARP inhibitor resistance
E. Gogola, NKI-AvL, Amsterdam
- 09.30 Response prediction for platinum-based treatment regimens in non-small cell lung cancer using a protein-based assay
F. Böttger, VUMC, Amsterdam
- 09.45 Functional analysis of BRCA1 variants and domains to improve genetic counselling and cancer treatment strategies
P. Bouwman, NKI-AvL, Amsterdam
- 10.00 Targeting KDM6B to eradicate subpopulations of anthracycline-tolerant leukemia cells
H.J.M.P. Verhagen, VUMC, Amsterdam
- 10.15 Development of testicular cancer patient-derived xenograft models to test novel therapies to overcome cisplatin resistance
G. de Vries, UMCG, Groningen
- 10.30 Coffee/Tea**

Session IV: Microenvironment

Chairs: Pieter van den Velden and Alain de Bruin

- 11.00 The immune phenotype of uveal melanoma molecularly dissected with digital PCR and expression profiling
R. J. Nell, LUMC, Leiden
- 11.15 Heparan sulfate proteoglycans mediate Wnt/ β -catenin signaling in Multiple Myeloma by interacting with Wnts and R-spondins
Z. Ren, AMC, Amsterdam
- 11.30 Understanding the role of SOX4 in educating the mammary tumor niche
G. Roukens, UMC Utrecht, Utrecht
- 11.45 Genetic inactivation of E2F7 and E2F8 stimulates tumor angiogenesis in de novo skin cancer and tumor xenografts
W. J. Bakker, Utrecht University and AMC, Amsterdam
- 12.00 **BIOKÉ presentation**
Edward Verwayen
- 12.15 **Lunch**
- 13.15 **Invited Lecture**
'Intravital imaging of Cancer plasticity'
Jacco van Rheenen, Hubrecht Institute, Utrecht

Session V: Genetics and Stem cells

Chairs: Leonid Bystrykh and Jan Jacob Schuringa

- 14.00 Genetic Landscape and Clonal Dynamics of Early Relapsed Pediatric BCP-ALL
Z. Antic, RadboudUMC, Nijmegen and PMC, Utrecht
- 14.15 Identification of oncogenic gene fusions in primary colon cancers
C. Stangl, UMC Utrecht, Utrecht
- 14.30 Coffee/Tea**

Session V: Genetics and Stem cells (*continued*)

- 15.00 Molecular characterization and targeting of non-canonical PRC1.1 in leukemic stem cells
V. van den Boom, UMCG, Groningen
- 15.15 R-spondin-3 is an oncogene in the intestine and mammary gland
E.R.M. Bakker, NKI-AvL, Amsterdam and UMC Utrecht, Utrecht
- 15.30 The identification of microRNAs involved in acute myeloid leukemia persistence
L. Smit, VUMC, Amsterdam
- 15.45 **Best presentation awards and closure**

